VIIV HLTHCARE
BiotechVIIV HLTHCARE is a biotechnology company focused on Infectious Disease, Immunology. Key products include TIVICAY.
FDA Novel Drug Designations
(2020-2021)See 2 novel approvals →
VIIV HLTHCARE's Key Drugs
VIIV HLTHCARE's core commercial portfolio centers on DOVATO, TIVICAY PD, RUKOBIA, spanning Infectious Disease and Immunology — its most strategically important drugs approved in the last 15 years.
HIV-1 Infection
HIV-1 Infection
Human Immunodeficiency Virus Type 1
HIV-1 Infection
HIV-1 Infection
VIIV HLTHCARE's Recent FDA Approvals
New NDA/BLA approvals for VIIV HLTHCARE over the last two years — novel drugs only, excluding generics and label supplements.
VIIV HLTHCARE's Therapeutic Areas
VIIV HLTHCARE's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Immunology, across 0 biologic and 12 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VIIV HLTHCARE's Top Competitors
VIIV HLTHCARE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VIIV HLTHCARE Pipeline Snapshot
Active clinical trials for VIIV HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (9)
Discontinued (1)
Company Info
- First Approval
- 1987-03-19
- Latest
- 2025-11-26
- Applications
- 26